These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32334104)

  • 1. The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers.
    Abrahamsen B; Ernst MT; Smith CD; Nybo M; Rubin KH; Prieto-Alhambra D; Hermann AP
    Bone; 2020 Aug; 137():115371. PubMed ID: 32334104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark.
    Ali MS; Ernst M; Robinson DE; Caskey F; Arden NK; Ben-Shlomo Y; Nybo M; Rubin KH; Judge A; Cooper C; Javaid MK; Hermann AP; Prieto-Alhambra D
    Arch Osteoporos; 2020 Jun; 15(1):81. PubMed ID: 32483674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study.
    Alarkawi D; Ali MS; Bliuc D; Pallares N; Tebe C; Elhussein L; Caskey FJ; Arden NK; Ben-Shlomo Y; Abrahamsen B; Diez-Perez A; Pascual J; Pérez-Sáez MJ; Center JR; Judge A; Cooper C; Javaid MK; Prieto-Alhambra D
    J Bone Miner Res; 2020 May; 35(5):894-900. PubMed ID: 31968134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density.
    Rodríguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Outcomes in the Years After a DXA-BMD Treatment Monitoring Test: Improved Medication Adherence in Some, But Too Little Too Late.
    Kline GA; Lix LM; Leslie WD
    J Bone Miner Res; 2021 Aug; 36(8):1425-1431. PubMed ID: 34029406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study.
    Jassal SK; von Muhlen D; Barrett-Connor E
    J Bone Miner Res; 2007 Feb; 22(2):203-10. PubMed ID: 17059370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and renal outcomes of low bone mineral density in patients with non-dialysis chronic kidney disease.
    Hyun YY; Lee KB; Han SH; Choi KH; Park HC; Oh YK; Park SK; Oh KH; Ahn C;
    Osteoporos Int; 2020 Dec; 31(12):2373-2382. PubMed ID: 32642852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
    Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
    Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis.
    Robinson DE; Ali MS; Pallares N; Tebé C; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey FJ; Cooper C; Dedman D; Delmestri A; Judge A; Pérez-Sáez MJ; Pascual J; Nogues X; Diez-Perez A; Strauss VY; Javaid MK; Prieto-Alhambra D
    J Bone Miner Res; 2021 May; 36(5):820-832. PubMed ID: 33373491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease is associated with low BMD at the hip but not at the spine.
    Bezerra de Carvalho KS; Vasco RFV; Custodio MR; Jorgetti V; Moysés RMA; Elias RM
    Osteoporos Int; 2019 May; 30(5):1015-1023. PubMed ID: 30693381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations.
    Uchiyama S; Ikegami S; Kamimura M; Mukaiyama K; Nakamura Y; Nonaka K; Kato H
    Bone; 2015 Jun; 75():84-7. PubMed ID: 25708052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience.
    Hauck D; Nery L; O'Connell R; Clifton-Bligh R; Mather A; Girgis CM
    Bone Rep; 2022 Jun; 16():101178. PubMed ID: 35281213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.